Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

Publisher： John Wiley & Sons Inc

E-ISSN： 1349-7006|107|9|1179-1186

ISSN： 1347-9032

Source： Cancer Science, Vol.107, Iss.9, 2016-09, pp. : 1179-1186

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

DNA methylation status as a biomarker of anti‐epidermal growth factor receptor treatment for metastatic colorectal cancer

By  

Cancer Science, Vol. 106, Iss. 12, 2015-12 ,pp. : 1722-1729

John Wiley & Sons Inc

Access to resources Recommend Favorite

Association between serum ligands and the skin toxicity of anti‐epidermal growth factor receptor antibody in metastatic colorectal cancer

By  

Cancer Science, Vol. 106, Iss. 5, 2015-05 ,pp. : 604-610

John Wiley & Sons Inc

Access to resources Recommend Favorite

Epidermal growth factor receptor and AKT1 gene copy numbers by multi‐gene fluorescence in situ hybridization impact on prognosis in breast cancer

By  

Cancer Science, Vol. 106, Iss. 5, 2015-05 ,pp. : 642-649

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I study of weekly nab‐paclitaxel combined with S‐1 in patients with human epidermal growth factor receptor type 2‐negative metastatic breast cancer

By  

Cancer Science, Vol. 106, Iss. 6, 2015-06 ,pp. : 734-739

John Wiley & Sons Inc

Access to resources Recommend Favorite

Novel Aurora/vascular endothelial growth factor receptor dual kinase inhibitor as treatment for hepatocellular carcinoma

By  

Cancer Science, Vol. 106, Iss. 8, 2015-08 ,pp. : 1016-1022

John Wiley & Sons Inc

Access to resources Recommend Favorite